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Proteinase-activated receptor 1 (PAR1) 
induces activation of platelet and vascular 
cells after proteolytic cleavage of its 
extracellular amino terminus by thrombin. 
In pathological situations, other 
proteinases may be generated in the 
circulation and might modify the 
responses of PAR1 by cleaving 
extracellular domains. In this study, 
epitope-tagged wild-type hPAR1 and a 
panel of N-linked glycosylation-deficient 
mutant receptors were permanently 
expressed in epithelial cells (KNRK and 
CHO cells). We have analysed the role of 
N-linked glycosylation in regulating 
proteinase activation/ disarming and cell 
global expression of hPAR1. We reported 
for the first time that glycosylation in the 
N-terminus of hPAR1 downstream of the 
tethered ligand (especially Asn
75
) governs 
receptor disarming to trypsin, 
thermolysin, and the neutrophil 
proteinases elastase and proteinase 3, but 
not cathepsin G. In addition, hPAR1 is 
heavily N-linked glycosylated and 
sialylated in epithelial cell lines, and 
glycosylation occurs at all five consensus 
sites, namely, Asn
35
, Asn
62
, Asn
75
, Asn
250
, 
and Asn
259
. Removing these N-linked 
glycosylation sequons effected hPAR1 cell 
surface expression to varying degrees, and 
N-linked glycosylation at ECL2 (especially 
Asn
250
) of hPAR1 is essential for optimal 
receptor cell surface expression and 
receptor stability.  
 
Proteinases can exert many 
biological effects on cells by virtue of their 
ability to cleave a plethora of protein 
substrates. Our understanding of proteinase 
signalling has advanced since the discovery 
of a small family of G-protein coupled 
receptors termed proteinase-activated 
receptors or PAR (1-3). Classically, 
thrombin activates PAR1 by proteolytic 
cleavage of the PAR1 N-terminal domain 
between Arg
41
 and Ser
42
 to expose a new N-
terminus that acts as a tethered-ligand and 
subsequently triggers receptor activation (2). 
Thrombin is a serine proteinase generated at 
the sites of vascular injury during the 
coagulation cascade and activates various 
types of cells in the vasculature like platelets 
and endothelial cells (2,3). In addition to 
thrombin, other proteinases may be 
generated in the circulation under 
pathological situations, any proteinase that 
cleaves the correct peptide bond within the 
N-terminus of PAR1 may be able to expose 
the tethered ligand and then initiate 
intracellular signalling to provoke a cellular 
response (1,2,4-8). Conversely, proteinases 
can also disarm PAR1 by proteolytic removal 
of the tethered ligand domain from the 
receptor (4,9-14). Such disarmed receptors 
remain at the cell surface but are no longer 
available for activation by activating 
proteinases (e.g. thrombin), they can 
however be activated by the corresponding 
PAR1-APs (1,2,15). Moreover, some of 
those proteinases (e.g. trypsin, neutrophil 
proteinases) have been reported to both 
activate and/or disarm PAR1 in different cell 
systems (2,4,8,13,14,16-18). Activation and 
desensitization of PAR1 must be well-
controlled in order to eliminate the potential 
pathological damage resulted from 
unchecked receptor signalling (14). 
Our previous pharmacological 
studies have reported that activation of 
hPAR2 by mast cell tryptase can be regulated 
by receptor N-terminal glycosylation (19,20). 
To our knowledge, hPAR1 contains a total of 
five predicted sites for N-linked 
glycosylation, three sequons are located on 
the receptor N-terminus (N
35
A
36
T
37
, 
N
62
E
63
S
64
, and N
75
K
76
S
77
) and two are 
located within extracellular loop 2 (ECL2; 
N
250
I
251
T
254
, and N
259
E
260
T
261
) (Fig. 1) (21). 
PAR1, downstream of the tethered ligand, 
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possesses two N-linked glycosylation 
sequons (Asn
62
 and Asn
75
) which are located 
along the N-terminus in a domain where 
disarming proteinases may target. In addition, 
previous studies demonstrated that 
thermolysin and neutrophil proteinases target 
specific sites which are close proximally to 
these glycosylation sequons (Fig. 1) 
(12,13,16). Hence, we have analysed the role 
of N-linked glycosylation in regulating cell 
surface expression and proteinase 
activation/disarming of hPAR1. We have 
permanently expressed epitope-tagged wild-
type or glycosylation-deficient mutant 
hPAR1 in KNRK and CHO (Pro5 and Lec2) 
cell lines and sought to determine: (i) the 
influence of  N-linked glycosylation sequons 
on the receptor cell surface expression and 
signalling, and (ii) the role of N-terminal 
glycosylation sequon, especially Asn
62
 and 
Asn
75
, in regulating receptor signalling by 
neutrophil proteinases and thermolysin. 
 
Experimental Procedure 
 
Materials- DMEM, sodium pyruvate, 
penicillin, streptomycin, amphotericin B, 
heat inactivated FCS, non-enzymic cell 
dissociation solution, geneticin (G418), 
Opti-MEM media and Lipofectamine 2000, 
dNTPs and Oligo(dT)12-18 primer, 
Accuprime DNA polymerase, Fluo-3 
acetoxymethyl ester were all purchased from 
Invitrogen Life Technologies Inc. (Paisley, 
UK). Primers were designed “in-house” and 
purchased from MWG-biotech (Ebersberg, 
Germany). PCR purification kits, Gel 
extraction kits, and plasmid isolation kits 
were all bought from Qiagen (Crawley, West 
Sussex, UK). XL1-Blue supercompetent 
cells and the QuikChange® Site-Directed 
Mutagenesis Kit were purchased from 
Stratagene® Europe (Amsterdam, NL). The 
rapid DNA ligation kit was bought from 
Roche (Lewes, East Sussex, UK). All 
restriction enzymes were purchased from 
New England Biolabs (Hitchin, 
Hertfordshire, UK). Anti-PAR1 ATAP-2 
monoclonal antibody was purchased from 
Zymed Laboratories Inc. (San Francisco, 
USA). PAR1-APs TFLLR-NH2 was 
purchased from Peptides International 
(Kentucky, USA). Enhanced yellow 
fluorescent protein (eYFP) was obtained 
from BD Biosciences Clontech (Alto, USA). 
Proteinase 3 was obtained from Athens 
Research & Technology (Athens Research & 
Technology, Inc. Athens, Greece). Human 
leukocyte elastase and cathepsin-G were 
purchased from Elastin Products (Elastin 
Products Company, Inc. Missouri, USA). M-
Per mammalian protein extraction reagent 
and the ProFound HA.11 
immunoprecipitation kit were purchased 
from PIERCE (PIERCE, Cheshire, UK). All 
other chemicals and reagents were purchased 
from Sigma-Aldrich (Poole, Dorset, UK) 
unless otherwise stated.  
Generation of cDNAs encoding wt-hPAR1E- 
Using an overlapping PCR approach, 
enhanced yellow fluorescent protein (eYFP) 
was fused to the C-terminal of wt-hPAR1 
(POMC-M1-hPAR1-HA.11 in pcDNA3.1: 
C-terminally tagged with an HA.11 epitope 
and N-terminally tagged with an M1 epitope 
and a Pro-opiomelanocortin (POMC)) to 
generate wt-hPAR1E (POMC-M1-hPAR1-
HA.11-eYFP). The wt-hPAR1E was 
subsequently amplified and purified, and 
then sequenced by MWG. 
Generation of glycosylation-deficient mutant 
cell lines- All glycosylation-deficient 
mutants  were generated using the 
QuickChange® site-directed mutagenesis kit 
and confirmed by MWG sequencing. The 
oligonucleotides were designed to replace 
the asparagine (N) residues at positions 
Asn
35
, Asn
62
, Asn
75
, Asn
250
, and Asn
259
 with 
glutamine (Q) residues. Single-site mutants 
(N35Q, N62Q, N75Q, N250Q, and N259Q) 
were first constructed. In order to elucidate 
the cumulative effects of a lack of 
glycosylation at multiple sites, four receptors 
with multiple glycosylation mutations 
(N62QN75Q, N35QN62QN75Q, 
N250QN259Q, and N35-259Q) were 
constructed. In addition, the alanine (A) 
mutations were created at amino acid 
position Phe
55
-Trp
56
 or Val
72
-Ser
73
 of 
N62QN75Q to generate cathepsin G mutant 
(F55AW56A) or proteinase 3 mutant 
(V72AS73A). KNRK and CHO cells 
permanently expressing wild type or mutant 
hPAR1 cell lines were generated and 
cultured as previously described (Table 1) 
(19,20). 
Flow Cytometry Analysis (FACs)- WT and 
mutant cells lines (approx. 90% confluence) 
with matched receptor expression were 
selected and used for further studies by 
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FACs (Becton Dickinson, Franklin Lakes, 
NJ, U.S.A.) as we previously described (19). 
The anti-PAR1 ATAP-2 monoclonal 
antibody (1µg/ml) and anti-mouse FITC-
conjugated antibody (1 in 1000 dilution) 
were applied to assess the levels of receptor 
cell-surface expression. The data was 
expressed as the median fluorescence of 
positive minus the median fluorescence of 
the EV (pcDNA3.1 transfected KNRK) cells.    
Confocal Microscopy Analysis- For the wt-
hPAR1eYFP and mutant cell lines, the light 
emitted by the eYFP (530 nm) fused to the 
receptor was used to assess receptor 
expression. Cells on coverslips were fixed 
by incubation in formaldehyde (3%) in PBS 
for 15 minutes at RT, and then permeabilised 
in PBS containing 0.2% triton X-100 for 10 
minutes at RT. The coverslips were then 
mounted with anti-fade and fixed to slides. 
The cells were visualised by a Nikon Eclipse 
(TE2000-E) microscope with a BioRad 
Radiance 2100 scanning system and lasers. 
Western Blot Analysis- HA.11 tagged wild 
type and glycosylation-deficient mutants of 
hPAR1E were immunoprecipitated using a 
ProFound HA.11 immunoprecipitation kit as 
per the manufacturer’s protocol. Protein 
samples (20g) were separated on a 10% 
SDS/PAGE gel before transfer to Hybond C 
PVDF membrane. The membrane was 
subsequently blocked with PBS containing 
5% non-fat milk before incubation overnight 
at 4°C with the mouse monoclonal HA.11 
antibody (1:1000 dilution in PBS/Tween-20 
(0.1%) containing 2% non-fat milk). Blots 
were washed with PBS/Tween 20 (0.1%) for 
1 h, replacing the buffer every 15 min, 
before a final incubation with the peroxidase 
conjugated goat anti-mouse IgG ([1 in 4000] 
in PBS/Tween-20 (0.1%) containing 2% 
non-fat milk) for 1 hour. Following a further 
wash in PBS/Tween 20 (0.1%) for 1 hour 
bands were visualized using ECL 
(Amersham Biosciences, UK). 
Calcium Signalling Assay- The calcium 
signalling assay was performed as we 
described previously (19). Functional 
receptor activity was assessed by challenging 
cells with the PAR1-AP TFLLR-NH2 (100 
µM) and thrombin (5 nM). To assess 
whether a test proteinase was amputating the 
tethered ligand from the receptor (disarming), 
cells were first challenged by addition of the 
test proteinase for 2 mins. Successful 
amputation of the tethered ligand was then 
monitored by a subsequent application of 
thrombin (5 nM). The calcium signal in 
response to thrombin will be ablated if the 
tethered ligand has been removed from the 
receptor by the test proteinase. To 
demonstrate that the disarmed PAR1 is still 
functional and present at the cell surface, 
100 µM TFLLR-NH2 was applied after 
thrombin challenge. A calcium signal 
triggered by the TFLLR-NH2 is indicative of 
a functional PAR1 at the cell surface, which 
is unresponsive to thrombin.  
Calculations and statistical analysis- Data 
were analyzed using Prism Graphpad 
software. Statistical tests were carried out 
depending on the specifics of the datasets to 
be compared. When a comparison of two 
cell lines subjected to the same treatment 
was compared, a paired student’s t test was 
adopted. The comparison of a group of cell 
lines subjected to the same treatment was 
performed by one-way ANOVA followed by 
Tukey's Multiple Comparison Test. In order 
to assess the changes over a period of time 
using a specific treatment or to assess a 
change over a concentration range between 
two different cell lines two-way ANOVA 
tables were adopted. 
 
RESULTS 
 
N-linked Glycosylation at Specific 
Sites Regulates hPAR1 Cell Surface 
Expression.  Flow cytometry analysis (FACS) 
demonstrated that removing any of the 
glycosylation sequons resulted in a 
significant decrease (p<0.001) in hPAR1 cell 
surface expression in KNRK cells (Fig. 2).  
N35Q displayed the greatest cell surface 
expression; N250Q displayed the lowest 
expression when compared to the other 
single mutants N35Q, N62Q, N75Q, N250Q 
and N259Q [percentage relative to WT ± 
SEM: 55 ± 4 %; 26 ± 3 %; 13 ± 1.5 %; 10.5 
± 0.7 % and 26 ± 3 % (n=3) respectively]. 
Removal of both glycosylation sequons on 
ECL2 (N250QN259Q) resulted in near total 
loss of cell surface expression [percentage 
relative to WT ± SEM: 6±1 % (n=3)]. In 
contrast removing all glycosylation sequons 
on the N-terminus (N35QN62QN75Q) still 
resulted in nearly 50% cell surface 
expression compared to WT expression 
[percentage relative to WT ± SEM: 44.7 ± 
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1 % (n=3)]. Removing all glycosylation 
sequons resulted in a receptor (N35-259Q) 
that was expressed at a similar level to the 
N250QN259Q mutant [percentage relative to 
WT ± SEM: 6 ± 1 % (n=3)].  
Analysis of eYFP tagged hPAR1 
localisation in permeabilized cells by 
confocal microscopy demonstrated that all 
hPAR1E types (wt and glycosylation-
deficient mutant hPAR1) with the exception 
of N35-259QhPAR1E were expressed on the 
cell surface; however, different levels of 
membrane localisation and cytosolic 
retention were observed (Fig. 3). There was 
no detectable fluorescence (eYFP signalling) 
observed in EV cells (Fig. 3A). Wt-hPAR1E 
displayed strong cell membrane expression 
with little receptor observed in the cytoplasm 
(Fig. 3B). Removal of sequon Asn
35
 in the 
receptor N-terminus resulted in the 
appearance of receptor within the cytosol 
(Fig. 3C). Removal of both sequons (Asn
62
 
and Asn
75
) after the tethered ligand of 
hPAR1 resulted in a large amount of receptor 
being found in the cytosol (Fig. 3D). The 
relative intensity of the receptor membrane 
localisation and global cellular distribution 
appeared to be reduced significantly after 
removal of ECL2 glycosylation sequons 
(Asn
250
 and Asn
259
) (Fig. 3E). Removal of all 
hPAR1 glycosylation sequons (Asn
35
, Asn
62
, 
Asn
75
, Asn
250
 and Asn
259
) resulted in a 
dramatic loss of cell surface expression with 
the highest level of receptor cytosolic 
retention (Fig. 3 F).  
hPAR1 is a Heavily Glycosylated 
and Sialylated Receptor.  All of the 
glycosylation-deficient mutant receptors 
displayed different degrees of loss in 
molecular mass; no bands were detected in 
EV cells (Fig. 4A). The molecular mass of 
WT-hPAR1E migrated as a broad band 
ranging from ~37 kDa to ~250 kDa, with the 
majority of the receptor being observed from 
~75 kDa to ~220 kDa. This is a similar 
pattern to that of N62QhPAR1E. 
N62QN75QhPAR1E migrated from ~37 kDa 
to ~120 kDa. N35QN62QN75QhPAR1E 
migrated with a molecular mass from ~37 
kDa to ~200 kDa, with the majority of the 
receptor being observed from ~75 kDa to 
~120 kDa. The predicted molecular mass of 
the fused hPAR1eYFP is approximately 
~70kDa to ~80 kDa (hPAR1 is ~47 kDa and 
eYFP protein is ~31 kDa). We proposed that 
the band at ~75 kDa may represent an 
unglycosylated monomer of PAR1; the bands 
around ~80kDa to ~130 kDa may represent a 
glycosylated monomer of PAR1; and the 
bands around ~150kDa to ~220 kDa may 
represent glycosylated and unglycosylated 
dimers of PAR1 (Fig. 4). When removing all 
three glycosylation sites (Asn
35
, Asn
62
,
 
Asn
75
) 
in the N-terminus of the receptor, the 
banding pattern changed with only 
glycosylated dimer and unglycosylated 
monomer present. Removal of glycosylation 
at sites Asn
62
 and Asn
75
 produced a single 
band at ~120 kDa representing a 
glycosylated monomer of PAR1. Only one 
band migrated at ~37 kDa from both 
N250QN259QhPAR1E and N35-
259QhPAR1E. A number of minor bands 
that may represent either eYFP protein or 
proteolytic degradation products of hPAR1 
were routinely observed around ~37 kDa in 
all lanes.  
To determine the contribution of 
sialic acid to the molecular mass of hPAR1, 
we performed western blot analysis for wt-
hPAR1E transfected CHO cells (Pro5 and 
Lec2) (Fig. 4B). No bands were detected in 
the non-transfected Lec2 and Pro5. Pro5-
PAR1E migrated as broad high molecular 
weight band ranging from ~25 kDa to ~200 
kDa; the molecular mass of Lec2-PAR1E 
ranged from ~25 kDa to ~150 kDa. Two 
bands were routinely observed between the 
~25 kDa to ~37 kDa ranges in both of Pro5-
PAR1E and Lec2-PAR1E. 
The N-linked Glycosylation Located 
After the Tethered Ligand of hPAR1 
Regulates hPAR1 Signalling.  To investigate 
whether N-linked glycosylation at individual 
residues had a role in regulating receptor 
function, we constructed calcium signalling 
concentration-effect curves for thrombin, 
trypsin and TFLLR-NH2, in wt-hPAR1 and 
hPAR1 glycosylation mutant KNRK cell 
lines. The EC50 values of wt-hPAR1 and 
mutant receptors for the calcium signalling 
assay are displayed in Table 2.  
N62QN75Q concentration effect 
curves were compared with WT-M since 
they displayed similar cell surface 
expression (p>0.05) (Fig. 5A). TFLLR-NH2 
displayed a slight rightward shift in 
activating N62QN75Q compared with WT-
M, stimulating a calcium signal at 3-100 µM 
for WT-M and 10-100 µM for N62QN75Q 
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respectively, but achieved the same 
maximum response of 42 ± 1.5% of A23187 
at 100 µM in both cell lines (Fig. 5B).  For 
N62QN75Q and WT-M, thrombin induced a 
calcium signal from 0.05 nM to 5 nM (Fig. 
5C). However, the magnitude of the 
responses to thrombin in N62QN75Q was 
smaller than those obtained for WT-M (24 ± 
2.6 % of A23187 and 31 ± 1.8 % of A23187 
respectively) (p>0.05). The EC50 value for 
thrombin in N62QN75Q was 0.3 nM and for 
WT-M was 0.12 nM. Interestingly, the 
N62QN75Q displayed reduced sensitivity 
towards trypsin compared to WT-M, and the 
maximal response achieved was only 14% of 
A23187 compared to 32 ± 3 % of A23187 
for the WT-M (p<0.001) (Fig. 5D). In 
addition, the EC50 value for trypsin in 
N62QN75Q was significantly greater than 
WT-M (42 nM and 26 nM respectively). 
However, further analysis of N62Q 
and N75Q cell lines, revealed no observable 
changes in receptor function for TFLLR-
NH2, thrombin or trypsin when compared 
with their matched wt-hPAR1 cell line (data 
not shown). 
Removal of N-linked Glycosylation 
Asn
62
 and/or Asn
75
 from hPAR1 Enhances the 
Ability of Trypsin to Disarm the Receptor.  
Having found that trypsin shows reduced 
activity towards N62QN75Q by calcium 
signalling assay, we then explored the ability 
of trypsin to disarm N62QN75Q, N62Q and 
N75Q.  
Fig. 6A shows the TFLLR-NH2 (100 
µM) responses following trypsin (3, 10, 30, 
100, 300 nM) and then thrombin (5 nM) 
challenge in WT-M and N62QN75Q cells 
(i.e. trypsin then thrombin and then TFLLR-
NH2). For WT-M the TFLLR-NH2 responses 
remained the same after challenging the cells 
with trypsin from 3-300 nM. Challenging the 
N62QN75Q cells with 3 nM trypsin 
followed by 5 nM thrombin, and then 100 
µM TFLLR-NH2, triggered a calcium signal 
that was similar to that seen for WT-M cells. 
However, a robust increase in the magnitude 
of TFLLR-NH2 triggered calcium signal was 
observed after challenging the N62QN75Q 
cells with 300 nM trypsin, which was over 
4-fold greater than that observed for WT-M 
cells (p<0.05). 
We next assessed whether individual 
glycosylation at Asn
62
 or Asn
75
 is 
responsible for regulating trypsin disarming 
of hPAR1 (Fig. 6B & C). Challenging N62Q 
cells with 5 nM thrombin or 100 µM 
TFLLR-NH2 resulted in a calcium response 
of 61.4 ± 6.7 % of A23187 and 62 ± 6.9 % 
of A23187 respectively (Fig. 6B). 
Challenging N62Q cells with 100 nM trypsin 
resulted in an observable calcium signal (32 
± 8 % of A23187). Addition of thrombin 
following trypsin challenge resulted in a 
marked reduction (p< 0.001) in the calcium 
response to thrombin compared with the 
response obtained with thrombin added 
alone (7.8 ± 1 % of A23187 vs. 61.4 ± 6.7 % 
of A23187). Addition of TFLLR-NH2 
following trypsin and thrombin resulted in a 
response that was slightly increased (p>0.05) 
in magnitude compared to the response 
obtained to TFLLR-NH2 following just 
thrombin addition (17.5 ± 3.6 % of A23187 
vs. 9 ± 3 % of A23187), but was 
significantly reduced (p< 0.001) compared 
with the response of TFLLR-NH2 added 
alone (17.5 ± 3.6 % of A23187 vs. 62 ± 
6.9 % of A23187). 
Challenging N75Q cells with trypsin 
only resulted in a response 8 ± 1 % of 
A23187 (Fig. 6C). Challenging N75Q cells 
with TFLLR-NH2 or thrombin alone resulted 
in a calcium response of 27 ± 2 % of 
A23187 and 12 ± 0.7 % of A23187 
respectively. Addition of TFLLR-NH2 
following thrombin addition resulted in a 
calcium response 12 ± 1.7 % of A23187. 
Addition of thrombin following addition of 
trypsin resulted in no calcium response. 
Finally, challenging the cells with TFLLR-
NH2 following trypsin and thrombin addition 
triggered a calcium response 21 ± 2.7 % of 
A23187, which was of comparable (p>0.05) 
magnitude to the response obtained with 
TFLLR-NH2 alone. 
Elastase, Proteinase 3 and 
Thermolysin, but not Cathepsin G Displayed 
Enhanced Ability to Disarm 
hPAR1(N62QN75Q).  Effective proteinase 
receptor disarming was assessed by 
thrombin activation of the cells following 
proteinase addition.  For N62QN75Q and 
WT-M significant differences (p< 0.0001) in 
responses to 5 nM thrombin following the 
addition of elastase at different 
concentrations were observed (Fig. 7A). For 
WT-M no changes were observed in 
thrombin triggered calcium responses after 
the addition of 1 nM elastase, and the 
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thrombin triggered calcium response was 
totally ablated after addition of 15 nM 
elastase. The thrombin response curve for 
N62QN75Q shifted left half a log when 
compared to WT-M. For N62QN75Q the 
calcium signalling response to thrombin 
started to decrease after challenging the cells 
with 1 nM elastase (~80% of control 
Thrombin response). The thrombin triggered 
calcium response was totally ablated after 
challenging cells with 5 nM elastase.  
For N62QN75Q and WT-M no 
significant differences (p>0.05) in responses 
to 5 nM thrombin following the addition of 
cathepsin G from 10 nM to 300 nM were 
observed (Fig. 7B). The thrombin triggered 
calcium response was totally ablated after 
addition of 300 nM cathepsin G for both 
N62QN75Q and WT-M.  
For N62QN75Q and WT-M significant 
differences (p< 0.0001) in responses to 5 nM 
thrombin following the addition of 
proteinase 3 were observed (Fig. 7C). For 
WT-M no changes were observed in the 
thrombin triggered calcium response 
following the addition of 1000 nM 
proteinase 3. In contrast, significant 
decreases in the response to thrombin were 
observed in N62QN75Q following the 
addition of proteinase 3 from 1 nM to 1000 
nM. The thrombin triggered calcium signal 
was totally abolished after the addition of 
1000 nM proteinase 3. 
For N62QN75Q and WT-M significant 
differences (p< 0.0001) in responses to 5 nM 
thrombin following the addition of 
thermolysin at different concentrations were 
observed (Fig. 7D). The thrombin response 
curve after adding thermolysin at increasing 
concentration for N62QN75Q shifted 30-
fold to the left when compared to WT-M. 
For N62QN75Q the calcium signalling 
response to thrombin started to decrease 
after application of thermolysin at 3 nM 
(~80% of control thrombin response). The 
thrombin triggered calcium response was 
totally ablated after challenging N62QN75Q 
with 300 nM thermolysin. However, for 
WT-M the thrombin triggered calcium 
responses remained elevated at thermolysin 
concentrations up to 30 nM. The calcium 
signalling response to thrombin started to 
decrease following 100 nM thermolysin 
addition (~80% of thrombin control). The 
thrombin triggered calcium response in WT-
M was totally ablated after addition of 1000 
nM thermolysin. 
Molecular Evidence that Cathepsin 
G and Proteinase 3 are Disarming 
hPAR1(N62QN75Q).  Addition of 100 nM 
cathepsin G to N62QN75Q cells before the 
addition of 5 nM thrombin markedly reduced 
(p< 0.001) the response to thrombin 
compared with the response obtained with 
thrombin added alone (11 ± 2 % of A23187 
and 30 ± 5 % of A23187 respectively) (Fig. 
8A). In contrast, prior addition of cathepsin 
G failed to reduce the thrombin calcium 
signal in cathepsin G mutant cells when 
compared to the control (32.5 ± 8 % of 
A23187 and 36.5 ± 8 % of A23187 
respectively) (p>0.05). 
No observable calcium response to 
thrombin was observed when 300 nM 
proteinase 3 had been added to the 
N62QN75Q cells prior to thrombin 
challenge (Fig. 8B). In contrast, prior 
addition of proteinase 3 failed to reduce the 
thrombin calcium signal in the proteinase 3 
mutant cells, when compared to the response 
obtained with thrombin added alone (13 ± 
2 % of A23187 and 12.33 ± 2.5 % of 
A23187 respectively) (p>0.05) . 
Elastase, Cathepsin G, Proteinase 3 
and Thermolysin Mainly Disarm 
hPAR1(N75Q).  The ability of thermolysin 
and neutrophil serine proteinases to 
activate/disarm N62Q and N75Q was 
investigated (Fig. 9).  
Challenging N62Q cells with 5 nM thrombin 
or 100 µM TFLLR-NH2 resulted in a 
calcium response of 64.7 ± 7 % of A23187 
and 67.8 ± 5 % of A23187 respectively (Fig. 
9A). In addition, challenge with TFLLR-
NH2 following thrombin addition resulted in 
a calcium response of 9 ± 3 % of A23187.  
Thermolysin (50 nM) had no observable 
effect on calcium signalling in N62Q.  
Challenge with thrombin following 
thermolysin addition resulted in a calcium 
response at 53.5 ± 4.6% of A23187 which is 
comparable to that obtained with thrombin 
added alone (64.7 ± 7 % of A23187). 
Addition of TFLLR-NH2 following 
thermolysin and thrombin resulted in a 
similar calcium response to the response 
obtained with TFLLR-NH2 following just 
thrombin challenge (13.6 ± 4 % of A23187 
and 9 ± 3 % of A23187 respectively). 
Addition of 1.5 nM elastase had no 
7 
 
observable effect on calcium signalling in 
N62Q cells. Addition of thrombin following 
elastase addition resulted in a calcium 
response 49 ± 3.5 % of A23187. Addition of 
TFLLR-NH2 following the disarming with 
elastase and thrombin resulted in a similar 
calcium response to the TFLLR-NH2 
response obtained following just thrombin 
alone 12 ± 1 % of A23187 and 9 ± 3 % of 
A23187 respectively). Addition of 100 nM 
cathepsin G had no observable effect on 
calcium signalling in N62Q cells. After 
challenging N62Q cells with cathepsin G, 
addition of thrombin resulted in a small 
decrease in the calcium response compared 
to that obtained with thrombin added alone 
(39 ± 3.8 % of A23187 and 64.7 ± 7 % of 
A23187 respectively). Addition of TFLLR-
NH2 following the addition of thermolysin 
and thrombin triggered a calcium response at 
16 ± 6 % of A23187 that was slightly larger 
than that obtained with TFLLR-NH2 
following thrombin alone (9 ± 3 % of 
A23187). Addition of 300 nM proteinase 3 
had no observable effect on calcium 
signalling in N62Q cells. Challenge with 
thrombin following proteinase 3 addition 
resulted in a calcium response 67 ± 6.7 % of 
A23187 which is comparable to that 
obtained when thrombin was added alone 
(64.7 ± 7 % of A23187). Addition of 
TFLLR-NH2 following the addition of 
proteinase 3 and thrombin resulted in a 
calcium response similar to that obtained 
with TFLLR-NH2 following thrombin 
addition (11.6 ± 4 % of A23187 and 9 ± 3 % 
of A23187 respectively). 
Challenging N75Q cells with 
thrombin or TFLLR-NH2 resulted in a 
calcium response 12 ± 0.7 % of A23187 and 
27 ± 2 % of A23187 respectively.  Addition 
of TFLLR-NH2 following thrombin 
challenge resulted in a calcium response 
13.6 ± 1 % of A23187 (Fig. 9B). No 
observable calcium response was detected 
after challenging N75Q cells with 
thermolysin. After challenging N75Q cells 
with thermolysin, addition of thrombin 
resulted in a calcium response which was 
comparable to that obtained to thrombin 
alone (10 ± 1 % of A23187 and 12 ± 0.7 % 
of A23187 respectively), and finally 
challenging the cells with TFLLR-NH2 
triggered a calcium response 21 ± 2 % of 
A23187. No observable calcium response 
was detected after challenging N75Q cells 
with elastase or with thrombin following the 
addition of elastase. In addition, the response 
to TFLLR-NH2 following elastase and 
thrombin challenge was the same as that 
obtained with TFLLR-NH2 alone (28 ± 1 % 
of A23187 vs. 27 ± 2 % of A23187).   
Addition of cathepsin G had no 
observable effect on calcium signalling in 
N75Q cells. Challenging cells with thrombin 
following the addition of cathepsin G 
resulted in a calcium response 10 ± 1 % of 
A23187 which was comparable to that 
obtained with thrombin alone (12 ± 0.7 % of 
A23187). Addition of TFLLR-NH2 
following the addition of cathepsin G and 
thrombin triggered a calcium response, 
which was of similar magnitude to that 
obtained with TFLLR-NH2 following 
thrombin alone (17 ± 1 % and 13.6 ± 1 % of 
A23187 respectively). Addition of 
proteinase 3 had no observable effect on 
calcium signalling in N75Q cells. Addition 
of thrombin after challenging N75Q cells 
with proteinase 3 resulted in a very small 
decrease in calcium response compared to 
that obtained with thrombin alone (10 ± 
0.5 % of A23187 and 12 ± 0.7 % of A23187 
respectively). Finally challenging the cells 
with TFLLR-NH2 following proteinase 3 
and Thrombin addition triggered a calcium 
response 20.5 ± 0.5 % of A23187. 
 
DISCUSSION 
 
In the present study, we have 
demonstrated for the first time that N-linked 
glycans (Asn
62
 and Asn
75
) after the tethered 
ligand on the N-terminus of hPAR1 regulate 
receptor signalling to trypsin, thermolysin 
and the neutrophil proteinases elastase and 
proteinase 3, but not cathepsin G. In addition, 
we reported that hPAR1 is heavily N-linked 
glycosylated and sialylated in epithelial cell 
lines (KNRK and Pro5 cells), and 
glycosylation occurs at all five consensus 
sites, namely, Asn
35
, Asn
62
, Asn
75
, Asn
250
, 
and Asn
259
. Removing N-linked 
glycosylation sequons at these positions 
affected hPAR1 cell surface expression to 
varying degrees, and N-linked glycosylation 
at ECL2 (especially Asn
250
) of hPAR1 might 
be essential for optimal receptor cell surface 
expression and receptor stability. 
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N-linked glycosylation, which adds 
oligosaccharides to the nitrogen in the side-
chain amide of asparagines residues, requires 
the asparagines in a consensus sequence of 
Asn-X-Ser/Thr (where X is any amino acid 
except proline) (22,23). However, not all 
consensus sites are actually glycosylated as 
the oligosaccharide might be trimmed and 
elaborated during transit through the 
endoplasmic reticulum (ER) and the Golgi 
apparatus (23). Disrupting the glycosylation 
sites by mutagenesis, individually and/or in 
combination, allowed us to investigate the 
status and even the function of each specific 
putative N-linked glycosylation site. 
We first examined the role of N-
linked glycosylation in regulating the 
receptor cell surface expression and the 
receptor global distribution in KNRK cells. 
Interestingly unlike previous studies in HeLa 
(24), there is still a very high level of cell 
surface expression of hPAR1 when removing 
all glycosylation sites on the N-terminus. 
The ECL2 single glycosylation mutant 
N250Q displayed the lowest level of cell 
surface expression of hPAR1 among all the 
other single glycosylation mutants; 
furthermore, removing all glycosylation 
sequons on ECL2 resulted in similar low 
levels of receptor cell surface expression to 
the non-glycosylation mutant where all 
glycosylation sequons had been deleted. N-
linked glycosylation of hPAR1 on ECL2 
(especially Asn
250
) versus glycosylation in 
the N-terminus might therefore be more 
important for receptor optimal cell surface 
expression. Glycosylation on ECL2 of PAR2 
is also important for enhancing receptor 
expression but not regulating receptor 
signalling; more importantly the ECL2 
region is extremely sensitive to mutations 
and mutating residues in and around the 
glycosylation sequon, even neutral mutations 
such as alanine (Ala) in ECL2 glycosylation 
sequon alters receptor structure and function 
(19,24). The PAR1 glycosylation study on 
HeLa cells reported that N-terminal N-linked 
glycosylation of PAR1 versus  ECL2 N-
linked glycosylation are critical for the 
regulation of  PAR1 signalling and 
trafficking (24). In this study, mutants were 
generated by substituting alanine (Ala) for 
glutamine (Glu).  It is therefore hard to 
determine whether the altered hPAR1 cell 
surface expression and signalling in HeLa 
cells is as a result of the loss of N-linked 
glycosylation or due to the Ala substitution 
altering receptor structure and function. We 
have generated our N-linked glycosylation 
mutants by substituting asparagine (Asn) for 
glutamine (Glu) at all five potential N-linked 
glycosylation sites, Glu is chemically and 
structurally more similar to Asn.
 
For this 
reason, we propose that this substitution 
itself will not lead to structural and 
functional differences between the
 
mutants 
and wild-type hPAR1, and any differences 
detected should be due to the loss of 
glycosylation.  
Using confocal microscopy we 
demonstrated that the glycosylation-deficient 
mutants, were abundant in the cytosol.  
Removal of a single N-terminal glycan 
resulted in observable receptor cytosolic 
retention, but removal of all glycosylation 
sites produced a receptor which could 
mainly be seen in the cytosol with minimal 
cell surface expression. Therefore, we 
conclude that N-linked glycosylation of 
hPAR1 at all sites might be required for the 
optimal receptor cell surface expression 
(24,25). 
Similar to Soto’s study (24), we 
have demonstrated that in KNRK cells 
hPAR1 is heavily glycosylated and the 
glycosylation occurs at all five consensus 
sites. Removal of N-linked glycosylation 
from ECL2 or removal of all N-linked 
glycans from the receptor resulted in only a 
single western blot band visualised at around 
37kDa compared with wild type or the N-
terminus mutants which produced a second 
band at a lower molecular weight. It is well 
known that N-linked glycosylation can 
regulate receptor conformation,
 
folding, or 
stability and even protecting receptors from 
proteolytic degradation. The bands shown 
around ~37kDa may represent either eYFP 
protein or deglycosylation/ or proteolytic 
degradation products of hPAR1 (5,14,24,26-
28). We thus propose that N-linked 
glycosylation especially on ECL2 (Asn
250
 
and Asn
259
) of hPAR1 might be vital for 
receptor stability and even protecting hPAR1 
from endogenous proteolytic degradation.  
Furthermore, we expressed the hPAR1 in 
CHO cells (Pro5 and Lec2) in order to assess 
the sialylation status of hPAR1. The Pro5 
cell line is the parent clone for the Lec2 cell 
line which has a substantial loss in ability to 
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attach sialic acid to the terminal positions on 
oligosaccharides. Western blot analysis of 
hPAR1 in Lec2 cells revealed a protein that 
had a molecular mass that was up to ~47 
kDa lower than that observed for hPAR1 
expressed in the Pro5 cells. Presumably this 
significant loss of ~47 kDa is due to the loss 
of receptor-associated sialic acid, and we can 
therefore conclude that hPAR1 in Pro5 cells, 
at least, is a heavily sialylated receptor.  
In order to establish the role of N-
linked glycosylation on the N-terminus of 
hPAR1 in regulating receptor function, 
agonist concentration effect curves were 
produced for the glycosylation-deficient 
hPAR1 cell lines and their respective wt-
hPAR1 cell line to evaluate the coupling of 
the mutant receptors to calcium. Receptor 
cell surface expression for each mutant cell 
line was compared and matched by FACs to 
wt-hPAR1 cells in order to ensure any 
functional differences detected were not due 
to differences in receptor cell surface 
expression (19). Except N62QN75Q mutant, 
no significant changes in receptor function 
were detected when compared with their 
respective matching wt-hPAR1 for all mutant 
cell lines. This N62QN75Q mutant displayed 
a slight reduction in sensitivity towards 
lower concentrations of TFLLR-NH2 and 
thrombin although statistical analysis 
showed no significant differences in EC50 
value and receptor maximum calcium 
signalling response towards 100 µM 
TFLLR-NH2 or 5nM thrombin.  The biggest 
reduction in agonist sensitivity was observed 
with trypsin activation. PAR1 coupling to 
calcium signalling appears not to be affected 
by the lack of glycosylation on the receptor. 
Even the N35-259Q mutant cell line still 
displayed a detectable calcium signal 
towards TFLLR-NH2 and thrombin (data not 
shown); thus adding strength to this 
conclusion.  
In our experiments trypsin triggered 
calcium signalling in wild-type hPAR1 and 
its mutants to varying degrees. However, 
TFLLR-NH2 calcium signalling response 
after addition of trypsin and thrombin is 
much greater in N62QN75Q 
mutants compared to wild-type hPAR1. This 
just confirmed that trypsin disarms the 
mutant receptor, and the disarmed mutant 
receptors still remained on the cell surface 
but cannot be activated by thrombin 
anymore as the tethered ligand has been 
removed, however, TFLLR will still activate 
those mutant receptor by binding to receptor 
ECL2. Trypsin can activate PAR1 by 
cleaving at the activating cleavage site 
Arg
41
-Ser
42
 to expose the tethered ligand 
(2,4,29). Moreover, trypsin has also been 
reported to cleave PAR1 at residues Arg
70
-
Leu
71
 and Lys
82
-Gln
83
 which amputates the 
tethered ligand from the receptor (4) (Fig. 1). 
Furthermore these residues are suggested to 
be cleaved by trypsin much faster than the 
residues Arg
41
-Ser
42
 (9). Given that these 
two potential trypsin cleavage sites are 
located close to Asn
75
, it is not surprising 
that in the N62QN75Q and N75Q mutants 
trypsin can gain easy access to these 
cleavage sites and therefore disarm these 
mutant receptors. In contrast, when PAR1 is 
fully glycosylated at Asn
75
 these cleavage 
sites are subsequently shielded by the 
attached oligosaccharide and thus trypsin 
disarms wt-hPAR1 less efficiently. 
Interestingly, Nakayama’s previous study 
reported that 100 nM trypsin cleaved PAR1 
but did not activate it in HUVEC cells, thus 
suggesting receptor disarming (9). We 
therefore assume that the glycosylation 
status of PAR1 in HUVEC cells must be 
different to our PAR1-KNRK system. Indeed, 
previous studies reported that PAR1 
expressed in HUVECS and platelets 
migrated as a homogenous species with an 
apparent mass of 66 kDa (27). This 
molecular mass is considerably below that 
reported in other cell systems, including ours, 
and suggests that PAR1 is not so heavily 
glycosylated in these cell types. Therefore 
we suggest that the Asn
62
 and Asn
75
 might 
not be fully glycosylated in HUVECs and 
therefore these potential trypsin cleavage 
sites around Asn
75 
are more readily available 
for trypsin cleavage, and subsequent disarms. 
We have also shown that the 
neutrophil proteinases elastase, cathepsin G 
and proteinase 3 do not activate PAR1 in our 
KNRK cell system, but rather disarm the 
receptor. Like us, Renesto and co-workers 
reported that elastase, cathepsin G and 
proteinase 3 can cleave and inactivate PAR1 
in platelets and human endothelial cells (13). 
In contrast, Suzuki and colleagues reported 
that elastase can activate PAR1 in human 
lung epithelial cells and also mentioned that 
proteolytic cleavage of PAR1 by elastase 
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might activate or inactivate the receptor 
depending on the site of cleavage (8). The 
authors also suggested that the extent of 
glycosylation of the receptor could influence 
the site and extent of cleavage of the 
receptor (8).  
In our current study, we note that 
elastase disarms N62QN75Q better than wt-
hPAR1 at the same concentration, and 1.5nM 
elastase disarms N75Q, but not N62Q. 
Renesto and colleagues’ mass spectrometry 
study indicated that elastase cleaves the N-
terminus of hPAR1 at Val
72
-Ser
73
 and Ile
74
-
Asn
75
 that are located after the tethered 
ligand (13). Furthermore, Loew et al. 
reported that elastase cleaved the PAR1 
exodomain at Ala
36
-Thr
37
, Val
72
-Ser
73
 and 
Ala
86
-Phe
87
 sites with preferential cleavage 
at Val
72
, which would disable the receptor 
(4). Therefore after amputating the Asn
75 
glycosylation, the potential cleavage sites 
Val
72
-Ser
73
 might be more easily accessible 
for elastase cleavage. 
Since cathepsin G has been reported 
to have both activating and disarming 
actions on PARs (12,13,30,31), we tested the 
role of N-terminal glycosylation of hPAR1 in 
regulating this proteinase. We have 
demonstrated that cathepsin G could clearly 
disarm N62QN75Q and wt-hPAR1 to the 
same efficiency. In addition, our data also 
revealed that cathepsin G at 100 nM disarms 
N62Q and N75Q. Like us others have also 
reported that cathepsin G at 30nM could 
disarm PAR1 (30). Molino et al. reported 
that in addition to the Arg
41
-Ser
42
 site, 
cathepsin G cleaves PAR1 at Phe
43
-Leu
44
 and 
Phe
55
-Trp
56
 removing the tethered ligand and 
rendering the receptor unresponsive to 
thrombin (12). In 1997 Renesto and 
colleagues’ mass spectrometry study 
indicated that cathepsin G cleaves PAR1 on 
platelets and endothelial cells downstream of 
the thrombin cleavage site at Phe
55
-Trp
56
 and 
Tyr
69
-Arg
70
 (13). Thus we then concluded 
that cathepsin G might have four potential 
cleavage sites in the N-terminus of hPAR1 
(Arg
41
-Ser
42
, Phe
43
-Leu
44
, Phe
55
-Trp
56
, and 
Tyr
69
-Arg
70
). Furthermore, Loew et al. 
kinetic analyses showed that the preferential 
cathepsin G cleavage site for PAR1 is Phe
55
-
Trp
56
 site (4). Moreover, our finding with the 
cathepsin G mutant is in accord with 
previous report that has demonstrated that 
Phe
55
-Trp
56
 is the main region cleaved within 
the receptor N-terminus by cathepsin G (12). 
Also, our western blot data revealed that 
Asn
62
 is not heavily glycosylated in our 
KNRK system. Therefore we suggest that 
cathepsin G sensitivity towards hPAR1 is not 
regulated by N-linked glycosylation.  
We have also assessed proteinase 3 
inhibition of thrombin-induced Ca
2+
 
mobilization in wt-hPAR1, N62QN75Q, 
N62Q and N75Q. Our data revealed that 300 
nM proteinase 3 disarms N62QN75Q but not 
wt-hPAR1, N62Q or N75Q. It is well 
established that proteinase 3 has an elastase-
like specificity for Ala, Ser, and Val at the 
P1 site (32). One previous study on human 
oral epithelial cells also pointed out that 
proteinase 3 can rapidly cleave PAR2 
between Arg and Ser and relatively 
inefficiently cleave between Lys and Val 
(33). Furthermore, proteinase 3 cleaved the 
peptide corresponding to the N-terminus of 
PAR2 at Arg
36
-Ser
37
 indicating that site of 
the PAR2 is structurally accessible by 
proteinase 3 (33). Interestingly, one previous 
study on synthetic peptides reported that the 
cleavage site for proteinase 3 in the N-
terminus of PAR1 is Val
72
-Ser
73
 (13). In 
addition, Loew and colleagues’ kinetic 
analysis on the N-terminus domain of PAR1 
showed that proteinase 3 early cleavage sites 
for PAR1 are Ala
36
-Thr
37
, Pro
48
-Asn
49
, Val
72
-
Ser
73
, Ala
92
-Ser
93
, and the late cleavage site 
is Pro
54
-Phe
55
 (4). Furthermore, Sokolova et 
al. suggested in a recent review that 
proteinase 3 cleaves human PAR1 at Ala
36
-
Thr
37
 and Val
72
-Ser
73 
(29). Although there 
are differences, previous studies have agreed 
that the Val
72
-Ser
73
 might be the earliest 
cleavage site for proteinase 3. We therefore 
altered that site by creating a mutation 
A
72
A
73
 in our N62QN75Q (named proteinase 
3 mutant), and indeed the proteinase 3 
almost immediately lost the ability to disarm 
the mutant receptor. As mentioned by Loew 
et al. there exists a late cleavage site 
between Pro
54
-Phe
55
, we therefore suggest 
that apart from the Val
72
-Ser
73
 cleavage site 
there might exist relatively inefficient later 
cleavage events between Pro
54
-Phe
55
, and 
possibly at Pro
48
-Asn
49
 (4). Thus there might 
be a possibility that if we expose PAR1 to 
proteinase 3 for a greater length of time, 
proteinase 3 might disarm wt-hPAR1. Indeed, 
we did notice that this phenomenon 
happened when we pre-incubated PAR1 with 
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proteinase 3 for more than 3 min (data not 
shown). We have shown that in wt-hPAR1 
cells, proteinase 3 does not disarm the 
receptor immediately (within 1 min), 
however, after the removal of the glycans in 
Asn
62
 and Asn
75
 proteinase 3 immediately 
disarmed the glycosylation mutant receptor 
and inhibited thrombin-induced calcium 
mobilization. We therefore suggest that 
glycosylation of Asn
62
 and Asn
75
 together 
regulate hPAR1 signalling to proteinase 3.  
Our data also revealed that 
thermolysin disarms N62QN75Q with 30 
fold better efficiency than wt-hPAR1. One 
previous study in insect SF9 cells reported 
that thermolysin may represent an important 
mechanism of rapid receptor deactivation of 
the human thrombin receptor (34). 
Furthermore, like us, one previous study for 
PAR1 in astrocytes found that treatment with 
thermolysin generated a thrombin-
insensitive receptor, whereas the response to 
the activating peptide was not affected (35). 
In the literature, it is well established that the 
predicted thermolysin cleavage sites in PAR1 
are within the tethered ligand domain 
(SFLLR) at
 
Phe
43
-Leu
44
 and Leu
44
-Leu
45
, 
suggesting that thermolysin would be 
expected to remove the exodomain of PAR1 
and destroy the tethered ligand and thus 
disarm the receptor (16,36). Interestingly, in 
our study system, removing both of the 
glycosylation sequons (Asn
62
 and Asn
75
) 
resulted in a receptor that was more 
efficiently disarmed by thermolysin, whereas 
removal of glycosylation at Asn
62 
sequon 
alone from the receptor had no observable 
effect on thermolysin disarming. However 
the N75Q did display increased disarming 
compared to wt-hPAR1, thus suggesting that 
this sequon regulates PAR1 disarming by 
thermolysin. Therefore, we predict that apart 
from the well established cleavage sites, 
there might be some other thermolysin 
cleavage sites in the N-terminus of PAR1 
especially in the region of the glycosylation 
site Asn
75
. In theory, bacterial thermolysin 
cleaves peptide bonds amino-terminally to 
the hydrophobic residues leucine and 
isoleucine, with some specificity for 
phenylalanine and valine (36). Therefore we 
suggest that Leu
71
- Val
72 
in PAR1 may also 
be a potential thermolysin cleavage site, and 
it is very close to Asn
75
 site. When 
amputating the Asn
75 
glycan this potential 
thermolysin cleavage site (Leu
71 
-Val
72
) will 
be more readily available for thermolysin 
cleavage. 
In summary, hPAR1 is a heavily 
glycosylated receptor and is important for 
cell surface expression, receptor stability and 
function.  We show here for the first time 
that glycosylation in the N-terminus of 
hPAR1 downstream of the tethered ligand 
(especially Asn
75
) governs receptor 
disarming to trypsin, thermolysin, and the 
neutrophil proteinases elastase and 
proteinase 3, but not cathepsin G. Thus we 
concluded that N-linked glycosylation at N-
terminus of hPAR1 plays a vital role in 
regulating the susceptibility to proteinase 
disarming of the receptor.  
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FOOTNOTES 
 
Abbreviations used are: KNRK, Kirsten murine sarcoma virus transformed rat kidney cells; 
CHO, Chinese hamster ovary cells; PCR, polymerase chain reaction; POMC, pro-
opiomelanocortin; eYFP, enhanced yellow fluorescent protein; hPAR1, human proteinase 
activated receptor-1; hPAR1E, human proteinase activated receptor-1 with eYFP tag; PAR1-
AP, PAR1 activating peptide; TF, TFLLR-NH2; TH, thrombin; THE, thermolysin; PR3, 
proteinase 3; CG, cathepsin G; ELA, human leukocyte elastase; 
 
FIGURE LEGENDS 
 
Fig. 1. Representative model of hPAR1 displaying the five potential N-linked 
glycosylation sequons and potential proteinase cleavage sites at the extracellular N-terminus. 
Three sequons are located on the receptor N-terminus (N
35
A
36
T
37
, N
62
E
63
S
64
, N
75
K
76
S
77
) and 
two are located within extracellular loop 2 (ECL2; N
250
I
251
T
254
, N
259
E
260
T
261
). Of the sequons 
at the N-terminus, one (N
35
A
36
T
37
) is located N-terminal of the cleavage/activation site 
(R
41
/S
42
FLLR) and the remaining two (N
62
E
63
S
64
, N
75
K
76
S
77
) are located downstream of the 
cleavage/activation site. The disulphide bridge is shown by the two cysteines (C-C).  The red 
arrows indicate the preferential cleavage site for each proteinase. TH, thrombin; TRY, trypsin; 
THE, thermolysin; PR3, proteinase 3; CG, cathepsin G; ELA, elastase. [Adapted from 
(4,12,13,29)]. 
 
Fig. 2.  Cell-surface expression of wt-hPAR1(WT) and glycosylation-deficient mutant 
hPAR1 receptor in KNRK cells assessed by FACs. Cells at approx 90% confluence were 
harvested and incubated with the ATAP-2 antibody before incubation with an anti-mouse 
FITC-conjugated antibody. Results are expressed as a percentage of the median fluorescence 
obtained with wt-hPAR1 cells. The bars represent mean ± SEM of measurements for three 
independent experiments. The overall comparsion showed that there were significant 
differences between 10 groups (p<0.0001). Tukey's Multiple Comparison Test indicated that 
the cell-surface expression of all the mutant receptors were significantly different from wt-
hPAR1 (p<0.001). 
 
Fig. 3.  Confocal microscopy for wt-hPAR1E and glycosylation-deficient mutants in 
KNRK cells. eYFP tagged PAR1 expressing KNRK cells were grown on coverslips before 
fixing and permeabilising. Cells were stained with propidium iodide prior to visualising. 
eYFP is visualised here in green and propidium iodide in red. I: cell surface expression, II:  
internal receptor expression. Green bar on the right of each panel stands for 10µm scale bar. 
A, EV; B, wt-hPAR1E; C, N35QhPAR1E; D, N62QN75QhPAR1E; E, N250N259QhPAR1E; F, 
N35-259QhPAR1E. The images are representative for four independent experiments. 
 
Fig. 4. Western blot analysis for wild-type and glycosylation-deficient mutant hPAR1. 
(A) Immunoprecipitates from KNRK cell lines expressing HA.11-tagged hPAR1 with the 
potential N-linked glycosylation sequons removed, were analysed by SDS/PAGE (10% gel) 
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and immunoblotted using HA.11 monoclonal antibody. Lane 1, EV; Lane 2, WT-hPAR1E; 
Lane 3, N62QhPAR1E; Lane 4, N62QN75QhPAR1E; Lane 5, N35QN62QN75QhPAR1E; 
Lane 6, N250N259QhPAR1E; Lane 7, N35-259QhPAR1E.  (B) Protein samples of hPAR1E 
transfected CHO (Pro5 and Lec2) cell lines were immunoprecipitated by HA.11 
immunoprecipitation and were analysed by SDS/PAGE (10% gel) and immunoblotted using a 
monoclonal HA.11 antibody. Lane 1, Pro5; Lane 2, Pro5-PAR1E; Lane 3, Lec2; Lane 4, 
Lec2-PAR1E. GD indicates glycosylated dimer; NGD, nonglycosylated dimer; GM, 
glycosylated monomer; NGM, nonglycosylated or minimally glycosylated monomer. M 
indicated nonglycosylated or minimally glycosylated monomer; D, PAR1 dimer. M.M., 
molecular mass. Results are representative of three separate experiments.  
 
Fig. 5.  Cell surface expression and calcium signalling analysis of WT-M and 
N62QN75Q. (A) Comparison of WT-M and glycosylation-deficient mutant N62QN75Q  
KNRK cell-surface expression. Cells at approx 90% confluence were harvested and incubated 
with the ATAP-2 antibody before incubation with an anti-mouse FITC-conjugated antibody. 
Cell surface expression was assessed by FACS analysis. Results are expressed as a percentage 
of the median fluorescence obtained with WT cells. (B), (C), (D) Calcium signalling in the 
WT-M and glycosylation mutant N62QN75Q in response to TFLLR-NH2, thrombin and 
trypsin.  Results are expressed as the means ± SEM of at least four independent experiments.  
 
Fig. 6.  (A) Analysis of trypsin disarming in WT-M and N62QN75Q. Calcium 
imaging of fluo-3 loaded cells was used to assess 100 µM TFLLR-NH2 responses following 
trypsin and then 5 nM thrombin challenge in wt-hPAR1 and hPAR1(N62QN75Q) transfected 
KNRK cells.  The cellular response to TFLLR-NH2 after the addition of thrombin but without 
pre-treatment with trypsin is used as a % control. (B) Analysis of trypsin disarming in N62Q. 
hPAR1(N62Q) transfected KNRK cells calcium signalling response following the addition of 
100 nM trypsin, 5 nM thrombin, and 100 µM TFLLR-NH2 and then 2 M A23187.  (C) 
Analysis of trypsin disarming in N75Q. hPAR1(N75Q) transfected KNRK cells calcium 
signalling response following the addition of 100 nM trypsin, 5 nM thrombin, 100 µM 
TFLLR-NH2 and then 2 M A23187. TRY, Trypsin; TH, thrombin; TF, TFLLR-NH2. The 
data sets are expressed as mean ± SEM from three separate experiments. 
 
Fig. 7. Analysis of WT-M and hPAR1(N62QN75Q) calcium signalling following 
proteinase stimuli.  WT-M and N62QN75Q in KNRK cells were challenged by (A) the 
addition of elastase; (B) the addition of cathepsin G; (C) the addition of proteinase 3; (D) the 
addition of thermolysin followed by the addition of 5 nM thrombin, and finally the addition of 
2 M A23187. Results are expressed as mean ± SEM from at least three independent 
experiments. 
 
Fig. 8.  Molecular evidence that cathepsin G and proteinase 3 disarm 
hPAR1(N62QN75Q).  (A) CG mutant and (B) proteinase 3 mutant cells loaded with Fluo-3 
were stimulated by the addition of  either 100 nM cathepsin G, or 300 nM proteinase 3 for 
2mins and then challenged with 5 nM thrombin, followed by 100 µM TFLLR-NH2 and then 2 
M calcium ionophore (A23187). TH, thrombin; CG, cathepsin G; PR3, proteinase 3. 
Results are expressed as the mean ± SEM of at least two independent experiments. 
 
Fig. 9.  Analysis of hPAR1(N62Q) and hPAR1(N75Q) calcium signalling following 
proteinase stimuli. (A) N62Q and (B) N75Q cells loaded with Fluo-3 were stimulated by the 
addition of either 50 nM thermolysin, 1.5 nM elastase, 100 nM cathepsin G, or 300 nM 
proteinase 3 for 2mins and then challenged with 5 nM thrombin, followed by 100 µM 
TFLLR-NH2 and then 2 M A23187. TRY, Trypsin; TH, thrombin; TF, TFLLR-NH2; THE, 
thermolysin; ELA, elastase; CG, cathepsin G; PR3, proteinase 3. Results are expressed as the 
mean ± SEM of at least three independent experiments. 
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Table 1. Table showing KNRK and CHO fibroblast (Pro5 and Lec2) permanently 
expressing (A) wild type or (B) N-linked glycosylation mutant hPAR1 cell clones 
generated for this study. In order to obtain permanent receptor expressing cell lines, cells 
expressing high levels of hPAR1 were isolated by FACS using the ATAP-2 anti-PAR1 
antibody. The glycosylation mutants were named with an N followed by a number related to 
the relative position of the potential glycosylation site and a Q.  The alanine mutations were 
created at amino acid position Phe
55
-Trp
56
 or Val
72
-Ser
73
 of N62QN75Q to generate cathepsin 
G mutant (F55AW56A) or proteinase 3 mutant (V72AS73A). 
 
     (A) 
Name of Clones Receptor cell surface expression level Cell Type 
WT Maximum level of wt-hPAR1 cell surface expression KNRK  & CHO 
WT-hPAR1E Maximum level of wt-hPAR1E cell surface expression KNRK  & CHO 
WT-H Higher level of wt-hPAR1 cell surface expression KNRK 
WT-M Medium level of wt-hPAR1 cell surface expression KNRK 
WT-L Low level wt-hPAR1 cell surface expression KNRK 
 
(B) 
Name of Clones Consensus Sequence(s) Disrupted Cell Type 
N35Q Asn
35 KNRK 
N62Q Asn
62 KNRK 
N75Q Asn
75 KNRK 
N250Q Asn
250 KNRK 
N259Q Asn
259 KNRK 
N62QN75Q Asn
62 and Asn75 KNRK 
N35QN62QN75Q Asn
35, Asn62 and Asn75 KNRK 
N250QN259Q Asn
250 and Asn259 KNRK 
N35-259Q Asn
35, Asn62, Asn75, Asn250 and Asn259 KNRK 
N35Q hPAR1E Asn
35 KNRK 
N62QN75Q hPAR1E Asn
62 and Asn75 KNRK 
N250QN259QhPAR1E Asn
250 and Asn259 KNRK 
N35-259Q hPAR1E Asn
35, Asn62, Asn75, Asn250 and Asn259 KNRK 
Cathepsin G mutant  Asn
62 , Asn75, Phe55 and Trp56 KNRK 
Proteinase 3 mutant  Asn
62, Asn75, Val72 and Ser73 KNRK 
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Table 2. EC50 values for N-terminal glycosylation-deficient mutant hPAR1 and their 
respective matching cell surface expression of wt-hPAR1 agonist concentration effect 
curves. Cell clones with matched receptor expression assessed by FACS analysis were 
selected for functional studies. Where it was not possible to match receptor expression 
between the wt-hPAR1 cell line and a cell line expressing a mutant glycosylation receptor, the 
WT, WT-H, WT-M and WT-L with different cell confluence in order to reduce receptor 
expression were used and thus match the cell surface expression of the mutant cell line. 
Reduced receptor cell surface expression of the WT-H, WT-M and WT-L cell lines were 
confirmed by using FACS analysis. 
 
Cell lines with 
matched receptor 
expression 
EC50 
TFLLR 
[µM] 
Thrombin  
[nM] 
Trypsin  
[nM] 
WT-H 17 0.14 33 
N35Q 16 0.2 43 
WT-L 27 0.2 39 
N62Q 29 0.4 43 
N75Q 31 0.2 41 
WT-M 22 0.12 26 
N62QN75Q 30 0.3 42 
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Figure 3.  
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(A) 
 
 
 
(B)  
 
21 
 
 
Figure 5. 
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Figure 7. 
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Figure 8. 
 
 
(A) 
(B) 
25 
 
Figure 9. 
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